...
首页> 外文期刊>Neurosurgical review. >Aperius interspinous device for degenerative lumbar spinal stenosis: a review
【24h】

Aperius interspinous device for degenerative lumbar spinal stenosis: a review

机译:Aperius棘突间融合器治疗退行性腰椎管狭窄症

获取原文
获取原文并翻译 | 示例
           

摘要

With an aging population, degenerative lumbar spinal stenosis (DLSS) leading to neurogenic intermittent claudication (NIC) is a growing problem. For patients suffering from this condition, interspinous process distraction devices (IPDs) offer an effective and cheap alternative to conservative or decompressive surgery. Aperius is one such device that has been gaining popularity for its percutaneous insertion under local anesthetic, short operative time, and low risk of complications. The main objective of this review was to carry out a comprehensive search of the literature to evaluate the effectiveness and potential complications of Aperius. A database search, including PubMed, Clinical trials.gov, Cochrane (CENTRAL), MEDLINE, CINAHL, EMBASE, and Scopus, was carried out to identify relevant articles written in English reporting on complications with a minimum 12-month follow-up. The literature search resulted in six eligible studies; two nonrandomized comparative and four prospective case series were available. The analysis revealed that in total, 433 patients underwent treatment with Aperius, with all studies demonstrating an improvement in outcome measures. The average follow-up was 17 months with an overall complication rate of 10.62 %. Overall, the quality of evidence is low, suggesting that currently, the evidence is not compelling and further prospective randomized trials including cost-effectiveness studies are required.
机译:随着人口的老龄化,导致神经源性间歇性lau行(NIC)的退行性腰椎管狭窄症(DLSS)是一个日益严重的问题。对于患有这种疾病的患者,棘突间牵引装置(IPD)为保守或减压手术提供了一种有效且廉价的替代方法。 Aperius就是这样一种设备,因其在局麻药下经皮插入,手术时间短和并发症风险低而受到欢迎。这篇综述的主要目的是对文献进行全面搜索,以评估Aperius的有效性和潜在的并发症。进行了数据库搜索,包括PubMed,Clinical trials.gov,Cochrane(CENTRAL),MEDLINE,CINAHL,EMBASE和Scopus,以鉴定用英语撰写的有关并发症的文章,至少随访12个月。文献检索得出六项符合条件的研究。有两个非随机比较性案例和四个预期案例系列。分析显示,总共有433例患者接受了Aperius治疗,所有研究均显示结果指标有所改善。平均随访17个月,总并发症率为10.62%。总体而言,证据质量低,这表明目前证据不足,并且需要进一步的前瞻性随机试验,包括成本-效果研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号